BDBM294353 Methyl 4-cyano-2-({(3R,6-methyl-1-[(2-pyrimidin-2-ylphenyl)carbonyl]piperidin-3-yl)oxy}pyridine-3-carboxylate::US9586950, 20::US9586950, 25

SMILES COC(=O)c1c(O[C@@H]2CC[C@@H](C)N(C2)C(=O)c2ccccc2-c2ncccn2)nccc1C#N

InChI Key InChIKey=WTEXMGOAFNNVRP-UHFFFAOYSA-N

Data  4 KI  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 294353   

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294353(US9586950, 20 | Methyl 4-cyano-2-({(3R,6-methyl-1-...)
Affinity DataKi:  0.540nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294353(US9586950, 20 | Methyl 4-cyano-2-({(3R,6-methyl-1-...)
Affinity DataKi:  0.760nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294353(US9586950, 20 | Methyl 4-cyano-2-({(3R,6-methyl-1-...)
Affinity DataIC50: 7nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294353(US9586950, 20 | Methyl 4-cyano-2-({(3R,6-methyl-1-...)
Affinity DataIC50: 23.8nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294353(US9586950, 20 | Methyl 4-cyano-2-({(3R,6-methyl-1-...)
Affinity DataKi:  30.8nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294353(US9586950, 20 | Methyl 4-cyano-2-({(3R,6-methyl-1-...)
Affinity DataKi:  269nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294353(US9586950, 20 | Methyl 4-cyano-2-({(3R,6-methyl-1-...)
Affinity DataIC50: 417nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294353(US9586950, 20 | Methyl 4-cyano-2-({(3R,6-methyl-1-...)
Affinity DataIC50: 1.29E+3nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent